A REVIEW OF ABBV-744 IN COMBINATION WITH IMMUNOTHERAPY

In Section C, participants will acquire ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually ailment progression or the individuals are unable to tolerate the study drugs.Ubiquitin-relevant proteins that control The steadiness of essential Tremendous enhancer-me